Understanding genetic and immune factors in aggressive prostate cancer
Official title: Project #1
Funded at Howard University · NIH-11419208 · Data updated 2026-11-12
A study from Johns Hopkins and Howard University will look at why advanced prostate cancer behaves differently in African American men and try to find biomarkers to predict and improve outcomes.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Howard University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project start | September 20, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $169,433 |
| NIH project number | 5U54CA295337-03 |
| Project ID | NIH-11419208 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are men with locally metastatic or high-risk prostate cancer, particularly African American men, who can contribute tumor samples and clinical data.
✕Less likely to help
Patients without high-risk or metastatic disease or without access to tumor samples may see little direct benefit.
What this research studies
This project will collect and analyze tumor and immune system data from men with advanced prostate cancer to understand how genetics and the tumor environment influence disease progression. Researchers will compare primary tumors and metastases, using genomic and epigenomic profiling to identify markers linked to lethal disease. They will test in situ biomarker assays that reflect tumor genetics and the immune landscape, aiming to connect these features with ancestry and clinical outcomes. The study brings together experienced teams at JHU and HU to build a well-annotated high-risk cohort for meaningful insights into aggressive prostate cancer.
Why it matters
Potential benefit: If successful, patients could receive more accurate risk markers and personalized treatment ideas for aggressive prostate cancer.
How similar studies have gone: Previous work suggests tumor genetics and immune environment influence outcomes; this study builds on that by profiling metastatic disease in a targeted cohort.
Where this research is happening
-
Howard University
Washington, United States Active
Researchers
- Principal investigator: Hudson, Tamaro Syton — Howard University
- Study coordinator: Hudson, Tamaro Syton
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.